|
WO2008027557A2
|
|
Topiramate compositions and methods of enhancing its bioavailability
|
|
WO2008002471A2
|
|
Erosion-stabilized bioadhesive polymers functionalized or blended with catechol and derivatives thereof
|
|
US2008131492A1
|
|
Dosage forms for movement disorder treatment
|
|
US2010226855A1
|
|
Rate-Controlled Oral Dosage Formulations
|
|
WO2007002518A1
|
|
Delayed release or extended-delayed release dosage forms of pramipexole
|
|
EP1901720A2
|
|
Improved dosage forms for movement disorder treatment
|
|
AU2005285298A1
|
|
Multi-layer tablets and bioadhesive dosage forms
|
|
WO2006026592A2
|
|
Oral administration of poorly absorbed drugs, methods and compositions related thereto
|
|
WO2006026556A2
|
|
Bioadhesive rate-controlled oral dosage formulations
|
|
US2006045865A1
|
|
Controlled regional oral delivery
|
|
AU2005219443A1
|
|
Polymeric drug delivery system for hydrophobic drugs
|
|
US2005201974A1
|
|
Bioadhesive polymers with catechol functionality
|
|
WO2005032511A2
|
|
Nanoparticulate therapeutic biologically active agents
|
|
WO2004098570A1
|
|
Nanoparticulate bioactive agents
|
|
US2005064027A1
|
|
Bioadhesive drug delivery system with enhanced gastric retention
|
|
AU2002360549A1
|
|
Methods and products useful in the formation and isolation of microparticles
|
